News and Trends 5 Apr 2023 Cure Ventures launches with $350M to support life sciences companies Cure Ventures, a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, has closed its inaugural fund, Cure Ventures Fund I, L.P., at its targeted hard-cap of $350 million in capital commitments. The fund is supported by a syndicate of U.S. and internationally-based investors that includes state and city public pension […] April 5, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2023 Mosaic Therapeutics closes $28M series A funding Mosaic Therapeutics, Ltd has closed its $28 million series A funding round. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital. The company also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic Therapeutics’ pipeline […] April 5, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 Sofinnova Partners dives into digital medicine, funds new companies Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has launched a new investment strategy focused on digital medicine. The strategy, which has already seen Sofinnova Partners investing in biotech companies, will be headed by partners Edward Kliphuis and Simon Turner. Sofinnova Digital Medicine will back entrepreneurs innovating at […] March 31, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 €260M fund addresses dementia investment shortfall EQT Life Sciences has closed its inaugural LSP Dementia Fund, raising approximately €260 million ($283 million) in fee-generating assets under management, meeting the hard cap and surpassing the target fund size of €100 million ($108.9 million). The LSP Dementia Fund is dedicated to investing in companies that are developing breakthrough drug therapies and medical technologies […] March 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 31 Mar 2023 How has the collapse of the Silicon Valley Bank affected the biotech industry? When investors got wind of Silicon Valley Bank (SVB) being forced to sell its treasury bonds at a loss, owing in part to surging interest rates in the past year – a move by the Federal Reserve to counteract rising inflation – panic followed a bank run. And in a swift spur of events, the […] March 31, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2023 SR One closes biotech fund at $600M SR One, a transatlantic life sciences investment firm, has announced the close of its second fund at more than $600 million, exceeding its target of $500 million. Fund II is the second fund since SR One spun out from GlaxoSmithKline (GSK) in 2020 to form a fully independent investment firm. The diverse investor base of […] March 30, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023 Evotec receives $6.6M for tuberculosis drug discovery On World Tuberculosis Day, Evotec SE has announced that it has received a $ 6.6 million grant from The Bill & Melinda Gates Foundation for drug discovery to tackle tuberculosis. The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the company to progress a portfolio of TB […] March 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 Flare Therapeutics sees $123M oncology boost Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has announced a $123 million Series B financing. The financing was co-led by GordonMD Global Investments LP and Pfizer Ventures, with participation from existing investors Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest […] March 23, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2023 Etana secures funding for oncology pipeline PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured a new round of investment led by DEG followed by Yunfeng Capital, HighLight Capital and East Ventures. The round of financing will be used for further strengthening PT Etana Biotechnologies’ pipeline and portfolio especially in oncology. Currently, PT Etana Biotechnologies focuses on local biopharmaceutical production […] March 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2023 SpyBiotech receives more than $4 million to develop vaccine platform UK-based SpyBiotech has received a grant of more than $4 million from the Bill & Melinda Gates Foundation to build its SpyVector platform for the development of a cross-protective coronavirus vaccine. The platform, which is based on recombinant adenovirus – a viral vector which can induce cellular immunity – enables a covalent decoration with the […] March 20, 2023 - 2 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 16 Mar 2023 Mediar Therapeutics boosts fibrosis portfolio with $105M financing Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis, has announced a $105 million financing. This includes a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol […] March 16, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2023 Nanite receives funding to deliver genetic therapies to the lungs Nanite Inc. has announced an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technologies for the lung. This builds on the $6 million seed financing recently announced by the company. One of the most significant challenges in developing new therapies for patients with cystic fibrosis is effective drug […] March 15, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email